MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

Table 1 Clinical and pathologic characteristics of patients with ERBB2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab

Case ID	Size, largest (mm)	Clinical TNM	Clinical stage	ER IHC	PR IHC	HER2 copy number (Average)	HER2/CEP17 Ratio	Pathologic Stage	pCR
1	49	cT2N2M0	IIIA	pos	pos	9.1	4.1	ypT0N0	yes
2	47	cT2N0M0	IIA	neg	neg	7.4^c	3.7^c	ypTisN0	yes
3	37	cT2N0M0	IIA	neg	neg	18.5	8.4	ypTisN0	yes
4	12	cT1N1M0	IIA	pos	neg	19.2	9.6	ypT0N0	yes
5	60	cT3N1M0	IIIA	pos	neg	8.1	3.7	ypTisN0	yes
6	63	cT3N1M0	IIIA	neg	neg	20.0	11.1	ypT0N0	yes
7	20	cT4N1M0	IIIB	neg	neg	17.2	6.6	ypT0N0	yes
8	36	cT2N1M0	IIB	neg^a	neg^a	17.4	6.7	ypT0N0	yes
9	18	cT1N2M0	IIIA	pos	pos	11.3	4.5	ypT0N0	yes
10	28	cT4N1M0	IIIB	pos	pos	15.8	7.5	ypT0N0	yes
11	47	cT2N0M0	IIA	neg^a	neg^a	4.3	2.9	ypT0Nx	yes
12	36	cT2N0M0	IIA	neg	neg	13.2	5.5	ypT0N0	yes
13	37	cT4N0M0	IIIB	pos	pos	20.0	16.7	ypT0N0	yes
14	42	cT2N1M0	IIB	pos	neg	3.3	2.4	ypT0N0	yes
15	60	cT3N0M0	IIB	pos	pos	14.7	8.2	ypT0N0	yes
16	20	cT1N1M0	IIA	pos	pos	4.9	3.1	ypTisN1	no
17	60	cT4N1M0	IIIB	pos	pos	5.0	3.1	ypT3N0	no
18	64	cT3N0M0	IIB	pos	pos	16.1	14.6	ypT1miN0	no
19	51	cT3N1M0	IIIA	pos	pos	5.2	3.2	ypT1N0	no
20	40	cT2N1M0	IIIA	pos	pos	4.4	2.3	ypT2N1	no
21	21	cT2N1M0	IIIA	pos	pos	16.6	8.3	ypT1N0	no
22	35	cT4N1M0	IIIB	pos	neg^a	5.3	2.9	ypT3N0	no
23	86	cT3N1M0	IIIA	pos	pos	5.0	3.2	ypT1N1	no
24	27	cT2N1M0	IIIA	neg	neg	15.9	7.2	ypT1N2	no
25	43	cT2N1M0	IIIA	pos	pos	14.0	5.6	ypT1N0	no
26	60	cT4N2M0	IIIB	pos	pos	16.7	8.4	ypT3N1	no
27	29	cT2N2M0	IIIA	pos	pos	16.2	10.1	ypT1N2	no
28	73	cT3N0M0	IIB	pos	pos	9.1	3.5	ypT2N1	no
29	41	cT2N0M0	IIA	neg	neg	3.6^b	1.8^b	ypT1N1	no

Abbreviations: ER estrogen receptor, IHC immunohistochemistry, PR progesterone receptor, pCR pathologic complete response
^aCases reported as negative, < 5 %, prior to the 2010 ASCO/CAP Guidelines
^bERBB2 immunohistochemistry was 3+
^c ERBB2 genetic heterogeneity present; average ERBB2 copy number and ERBB2/CEP17 ratio reported for amplified clone

ISSN: 1471-2407